Assessment of HER-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma
Assessment of HER-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma
复制标题
DOI：
10.1097/00129039-200306000-00005
复制
发表时间：
2003-06-01
影响因子：
1.6
通讯作者：
Gattuso, P
中科院分区：
文献类型：
--
作者：
Anderson, JM;Ariga, R;Gattuso, P
HER-2/Neu过表达见于20%至30%的浸润性乳腺癌，并且已报道在多达80%的高级别浸润性癌中。早期的研究表明，乳腺佩吉特病的肿瘤细胞中100%的HER-2蛋白过表达。我们进行了这项研究，以评估乳腺佩吉特疾病和潜在的乳腺癌，如果存在，免疫组化（IHC）和荧光原位杂交（FISH）的HER-2状态。对20例乳腺佩吉特病石蜡包埋组织行免疫组化（IHC）和荧光原位杂交（FISH）检测HER-2表达。还进行了雌激素受体（ER）的IHC。患者的年龄范围为34至88岁，平均年龄为62岁。80%的病例通过IHC显示HER-2蛋白的强烈过表达（3+），并且所有这些病例通过FISH显示HER-2基因的扩增超过5倍。其余4例HER-2/Neu免疫组化阴性，FISH检测无扩增。所有后者的情况下，表达ER，而没有过表达HER-2表达ER的情况。16例有潜在肿瘤，其中6例为原位肿瘤。基础肿瘤与佩吉特病的HER-2/Neu过表达相同，均通过IHC和FISH检测。HER-2过表达率为80%。我们的佩吉特病病例在佩吉特和潜在肿瘤中，通过免疫组化和基因扩增检测HER-2蛋白过度表达之间的一致性为100%。此外，所有HER-2过表达阴性的病例均表达ER，而HER-2阳性的病例则不表达。
HER-2/Neu overexpression is seen in 20% to 30% of invasive breast carcinomas and has been reported in as many as 80% of high-grade infiltrating carcinomas. Earlier studies have suggested that 100% of the tumor cells in mammary Paget disease show overexpression of HER-2 protein. We undertook this study to assess HER-2 status of mammary Paget disease and of the underlying breast carcinoma, when present, by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Formalin-fixed, paraffin-embedded tissue from 20 cases of mammary Paget disease were analyzed for HER-2 status by IHC and FISH. IHC for estrogen receptor (ER) was also performed. The patients ranged in age from 34 to 88 years, with a mean age of 62 years. Eighty percent of the cases showed strong overexpression (3+) of HER-2 protein by IHC, and all of these cases showed more than 5-fold amplification of the HER-2 gene by FISH. The remaining 4 cases, which were negative for HER-2/Neu by IHC, showed no amplification by FISH. All of the latter cases expressed ER, whereas no case that overexpressed HER-2 expressed ER. Sixteen cases had an underlying tumor, which was in situ in 6 cases. The underlying tumors were identical to the Paget disease with respect to their HER-2/Neu overexpression by both IHC and FISH. HER-2 overexpression was identified in 80% of. our cases of Paget disease. There was 100% concordance between HER-2 protein overexpression by immunohistochemistry and gene amplification in both the Paget and the underlying tumor. Moreover, all, of the cases negative for HER-2 overexpression expressed ER, whereas those positive for HER-2 did not.